JPMorgan Chase & Co. Cuts Dyne Therapeutics (NASDAQ:DYN) Price Target to $17.00
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) had its target price cut by equities research analysts at JPMorgan Chase & Co. from $18.00 to $17.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside […]
More Stories
Corebridge Financial Inc. Purchases 2,483 Shares of Alkami Technology, Inc. (NASDAQ:ALKT)
Corebridge Financial Inc. increased its position in Alkami Technology, Inc. (NASDAQ:ALKT – Free Report) by 10.4% during the fourth quarter,...
Alphabet Inc. (NASDAQ:GOOGL) Stock Position Increased by Parametrica Management Ltd
Parametrica Management Ltd increased its stake in shares of Alphabet Inc. (NASDAQ:GOOGL – Free Report) by 8.8% in the 4th...
Anthracite Investment Company Inc. Buys 6,000 Shares of Alphabet Inc. (NASDAQ:GOOGL)
Anthracite Investment Company Inc. increased its stake in shares of Alphabet Inc. (NASDAQ:GOOGL – Free Report) by 85.7% in the...
JPMorgan Chase & Co. Reduces Position in Sonos, Inc. (NASDAQ:SONO)
JPMorgan Chase & Co. trimmed its position in Sonos, Inc. (NASDAQ:SONO – Free Report) by 6.6% during the fourth quarter,...
Innovative Industrial Properties, Inc. (NYSE:IIPR) Shares Sold by Corebridge Financial Inc.
Corebridge Financial Inc. lowered its stake in shares of Innovative Industrial Properties, Inc. (NYSE:IIPR – Free Report) by 7.2% in...
Corebridge Financial Inc. Sells 2,442 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)
Corebridge Financial Inc. cut its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 5.5% in the...